Alexandra Anamaria Oaie

Dr. Alexandra Anamaria Oaie

Gastroenterology, Clinical Emergency Hospital Bucharest, Bucharest, Bucureşti, Romania
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PCPavel Christopher
Pavel Christopher
APAna Maria Popa
Ana Maria Popa
MIMadalina Ilie
Madalina Ilie
OPOana Mihaela Plotogea
Oana Mihaela Plotogea
RDRaluca-Ioana Dascalu
Raluca-Ioana Dascalu
Alexandra Anamaria OaieAlexandra Anamaria Oaie
Alexandra Anamaria Oaie
Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic immune-mediated condition with substantial global burden and rising incidence, requiring an expanding range of advanced therapies. This focused narrative review examines the mechanistic rationale, comparative clinical evidence, and translational implications of approved and emerging targeted therapies for adult IBD. A structured literature search was conducted in PubMed, Scopus, and Web of Science for publications from January 2021 to March 2026. Thirty-eight articles were selected as the core evidence set with landmark trials and clinical guidelines added when needed for historical or practice context. Evidence was synthesised narratively, with an explicit distinction between direct head-to-head comparisons, placebo-controlled trials, indirect network comparisons, and observational data. In UC, VARSITY showed higher week-52 clinical remission and endoscopic improvement with vedolizumab than adalimumab; in CD after anti–tumour necrosis factor (anti-TNF) failure, SEQUENCE showed risankizumab noninferior to ustekinumab for week-24 clinical remission and superior for week-48 endoscopic remission. Agents targeting tumour necrosis factor-like cytokine 1A (TL1A) have shown encouraging activity in phase 2/2b trials, but long-term effectiveness and safety remain uncertain. The current evidence supports mechanism-informed rather than biomarker-defined treatment selection. Confidence in comparative conclusions is greatest when supported by direct randomised evidence, whereas observational and indirect comparisons require caution because of confounding, heterogeneity, and differences in populations and outcome definitions. Clinical translation therefore requires the integration of the disease phenotype, prior treatment exposure, safety risks, and patient preference, with objective reassessment after therapy initiation.

24 September 2025 in Documenta Haematologica - Revista Romana de Hematologie
Verified
Journal Article
Closed access
ACAlexandra Crinu
Alexandra Crinu
Alexandra Anamaria OaieAlexandra Anamaria Oaie
Alexandra Anamaria Oaie
GIGabriela Ivanov
Gabriela Ivanov
MMMariana Mihaila
Mariana Mihaila
DCDaniel Coriu
Daniel Coriu
IUIulia Ursuleac
Iulia Ursuleac
Introduction: Hereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is a rare autosomal dominant disorder characterized by mucosal and cutaneous telangiectasia and systemic vascular malformations. HHT can be diagnosed using the Curaçao criteria. If at least three criteria are met, the diagnosis of HHT is considered definite. Purpose: The objective of this study was to describe the clinical characteristics, management and complications of patients diagnosed with HHT and monitored in the Internal Medicine and Hematology Departments of the Fundeni Clinical Institute. Method: A descriptive and retrospective study consisting of 24 patients over ten years (2014-2024). Results: Out of 24 patients, 20 patients were women with a median age at the onset of symptoms of 28.3 years and at first admission in a clinical unit of 45.5 years. In 7 patients, genetic testing revealed mutations in the ACVRL1 and ENG genes. The most common reason for admission was nasal bleeding (91.6 %). The vascular malformations involved multiple visceral organs with the most common sites being the liver (50%), gastrointestinal tract (25%), lung (12.5%), pancreas (8.3%).. The management of the patients included blood transfusions, iron supply, argon plasma coagulation, radiological embolisation and liver transplantation. The main complications were due to upper gastrointestinal bleeding, heart failure and thrombosis. Conclusions: HHT is an extremely heterogenous disease. Subjects from the same family often present with different sites of vascular malformations. At the moment, only symptomatic options of treatment are available in referral centers in our country. Angiogenesis inhibitors are considered prospective therapeutic options that have shown promising results in various studies. Early identification and treatment of symptoms and complications are crucial for enhancing the quality of life for individuals with HHT.